Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average - Should You Sell?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report)'s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $9.33 and traded as low as $5.52. Karyopharm Therapeutics shares last traded at $6.07, with a volume of 133,530 shares changing hands.

Analysts Set New Price Targets

Several research firms have weighed in on KPTI. Robert W. Baird dropped their target price on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an "outperform" rating on the stock in a research report on Monday, March 3rd. HC Wainwright boosted their price objective on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a "buy" rating in a report on Wednesday, February 26th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $45.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.50.

Karyopharm Therapeutics Stock Performance

The firm's 50 day simple moving average is $5.69 and its 200 day simple moving average is $9.19. The firm has a market capitalization of $63.08 million, a price-to-earnings ratio of -7.22 and a beta of 0.32.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last posted its earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.90) by $0.30. The business had revenue of $30.54 million for the quarter, compared to analyst estimates of $30.29 million. As a group, sell-side analysts forecast that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current year.

Institutional Trading of Karyopharm Therapeutics

A number of hedge funds have recently added to or reduced their stakes in KPTI. Adage Capital Partners GP L.L.C. increased its stake in shares of Karyopharm Therapeutics by 46.3% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company's stock valued at $4,274,000 after purchasing an additional 2,000,000 shares in the last quarter. Marshall Wace LLP raised its stake in shares of Karyopharm Therapeutics by 15.3% during the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company's stock worth $1,633,000 after buying an additional 319,187 shares during the period. Geode Capital Management LLC lifted its position in shares of Karyopharm Therapeutics by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company's stock valued at $942,000 after buying an additional 36,922 shares in the last quarter. Jane Street Group LLC grew its stake in Karyopharm Therapeutics by 265.5% in the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company's stock valued at $506,000 after acquiring an additional 543,556 shares during the period. Finally, Silverarc Capital Management LLC increased its holdings in Karyopharm Therapeutics by 6.7% in the 4th quarter. Silverarc Capital Management LLC now owns 595,990 shares of the company's stock worth $403,000 after acquiring an additional 37,524 shares in the last quarter. 66.44% of the stock is owned by hedge funds and other institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).